Mitratapide
| Mitratapide | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mitratapide is a medication used to treat obesity in dogs. It is classified as a microsomal triglyceride transfer protein (MTP) inhibitor. By inhibiting MTP, mitratapide reduces the absorption of dietary fats, leading to weight loss in obese dogs.
Mechanism of Action[edit]
Mitratapide works by inhibiting the activity of microsomal triglyceride transfer protein (MTP), which is essential for the assembly and secretion of lipoproteins containing triglycerides and cholesterol. By blocking MTP, mitratapide reduces the absorption of dietary fats in the intestine, leading to a decrease in the overall caloric intake and promoting weight loss.
Indications[edit]
Mitratapide is specifically indicated for the management of obesity in dogs. It is not approved for use in other animals or in humans.
Dosage and Administration[edit]
The dosage of mitratapide is typically based on the dog's body weight and the severity of obesity. It is usually administered orally, and the treatment duration may vary depending on the response to the medication and the veterinarian's recommendations.
Side Effects[edit]
Common side effects of mitratapide may include:
In rare cases, more severe side effects may occur, and it is important to monitor the dog closely during treatment.
Precautions[edit]
Mitratapide should be used with caution in dogs with pre-existing liver disease or other significant health conditions. It is important to follow the veterinarian's instructions and to monitor the dog's health regularly during treatment.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
